Timothy M. Mayleben, President & CEO at Esperion Therapeutics, Inc. (ESPR), bought 5,000 shares at $39.56 ($198K) on 2019-08-01, disclosed to the SEC on 2019-08-02.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| ESPR | BUY | 2019-11-08 | $370K | — | Filing → |
| ESPR | BUY | 2019-09-06 | $259K | — | Filing → |
| ESPR | BUY | 2019-07-01 | $230K | — | Filing → |